Moderna, Inc. — Director's Dealing 2022

May 2, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2022-04-28

Reporting Person: SAGAN PAUL (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-04-28	Common Stock	M	703	—	Acquired	703	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-04-28	Restricted Stock Units	$0	M	703	Disposed		Common Stock (703)	Direct
2022-04-28	Stock Option (Right to Buy)	$142.52	A	5415	Acquired		Common Stock (5415)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	14951	Indirect
Common Stock	76452	Indirect
Common Stock	370407	Indirect

Footnotes

F1: Restricted stock units convert into common stock on a one-for-one basis.

F2: Erwin Park LLC is an investment vehicle owned by the Reporting Person's children. The Chatham Trust is an irrevocable family trust for which the Reporting Person serves as a trustee. The Paul Sagan Revocable Trust is a revocable trust for which the Reporting Person serves as a trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

F3: The shares subject to this restricted stock unit award vested in full on April 28, 2022.

F4: This option will become fully vested and exercisable on the earlier of April 28, 2023, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service.